Targeting bladder cancer, Oomni is developing an orally small molecule that simultaneously addresses both the cancer and resultant pain. The use of chemotherapy as a treatment option for over 50% of cancers - lung, breast, and bladder - yields limited clinical success due to tumor resistance and to severe side effects. To overcome resistance cancer chemotherapy usually consists of multiple drugs. However, that addition of more drugs also leads to even more side effects. Typically, more than half of patients do not respond to chemotherapy but do incur the toxic side effects. Oomni is developing a drug designed to improve a cancer patient treatment - extending overall survival - but also improving quality of life through the reduction of chemotherapy induced toxicities.
